Results 151 to 160 of about 125,674 (260)

Natural Products Targeting BCR-ABL: A Plant-Based Approach to Chronic Myeloid Leukemia Treatment. [PDF]

Molecules
Pechlivani L, Giannakis A, Sioka C, Alexiou GA, Kyritsis AP.   +4 more
europepmc   +1 more source

Exosome and BCR-ABL mediated molecular alterations in endothelial cells in chronic myeloid leukemia: identification of seven genes and their regulatory network. [PDF]

PeerJ
Shen Z, Cao H, Zhou Y, Mao W, Liu K, Zhu J, He M, Mao Y, Luo N, Feng L, Le H, Song L, Li H, Yousafzai YM, Zia A, Gu X, Zhang S.   +16 more
europepmc   +1 more source

Stem cells in chronic myeloid leukaemia [PDF]

, 2007
Holyoake, T., Pellicano, F.
core   +1 more source

Under ONIOM Layers: Analysis of BCR-ABL Enzyme Inhibitors Through Bond-Critical Points and Natural Orbitals. [PDF]

Molecules
Rocha KML, Nascimento ÉCM, Martins JBL.
europepmc   +1 more source

Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia. [PDF]

Pathol Oncol Res, 2023
Hasanova A, Asadov C, Karimova N, Shirinova A, Aliyeva G, Alimirzoyeva Z.   +5 more
europepmc   +1 more source

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

Cancer Cell, 2009
T. O'hare, W. Shakespeare, Xiaotian Zhu, C. Eide, V. Rivera, Frank Y. Wang, Lauren T. Adrian, Tianjun Zhou, Wei‐Sheng Huang, Qihong Xu, C. Metcalf, J. Tyner, M. Loriaux, A. Corbin, Scott D. Wardwell, Y. Ning, J. Keats, Yihan Wang, R. Sundaramoorthi, Mathew P. Thomas, Dong Zhou, Joseph T Snodgrass, L. Commodore, T. Sawyer, D. Dalgarno, M. Deininger, B. Druker, T. Clackson   +27 more
semanticscholar   +1 more source

BCR-ABL tyrosine kinase [PDF]

Science-Business eXchange, 2013
openaire   +3 more sources

Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib. [PDF]

Pharmaceuticals (Basel)
Hajjo R, Sabbah DA, Alhaded R, Alquabe'h A, Bardaweel SK.   +4 more
europepmc   +1 more source

The silent players: Atypical <i>BCR‑ABL </i>isoforms as biomarkers and therapeutic hurdles in CML pathogenesis (Review). [PDF]

Oncol Rep
Zhou X, Li A, Kong D, Shi Y, Zhang P, Shan N.   +5 more
europepmc   +1 more source

Lactate-mediated activation of GPR81 regulates BCR/Abl protein expression in chronic myeloid leukemia cells selected under low oxygen tension. [PDF]

J Pathol
Menegazzi G, Desideri D, Biagioni A, Rovida E, Dello Sbarba P, Peppicelli S.   +5 more
europepmc   +1 more source